Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Laboratory for Molecular Medicine, |
RCV001195233 | SCV001365540 | uncertain significance | not specified | 2019-03-25 | criteria provided, single submitter | clinical testing | The p.Gly724Ser variant has not been reported as a germline variant to our knowledge. However, this variant has been identified in 13 lung adenocarcinomas or non-small cell lung cancers (Brown 2019, Chung 2009, Fassunke 2018, Ogino 2005, Oztan 2017, Peled 2017, Tam 2006, Zhang 2019). In 11 of these cases, the p.Gly724Ser variant was only identified after progressive disease and in the setting of osimertinib and/or erlotinib resistance, often in the context of primary EGFR exon 19 deletions and acquired p.Thr790Met resistant mutation. Molecular modeling suggests that the p.Gly724Ser variant reduces osimertinib binding affinity in context of exon 19 deletion (Brown 2019), and in vitro functional evidence also supported that the p.Gly724Ser variant is resistant to osimertinib but may be responsive to afatinib (Brown 2019, Cho 2014, Fassunke 2018). This was also observed in one patient, where afatinib reduced the p.Gly724Ser clone identified in a metastatic liver lesion (Peled 2017). This variant has also been reported in two cases of colorectal cancer, one of which that did not respond to gefitinib (Cho 2014, Ogino 2005). In summary, while the clinical significance of this variant is uncertain in the context of a germline variant, there is evidence to support that the variant is likely resistant to osimertinib, a third-generation EGFR inhibitor in the setting of EGFR exon 19 deletions with or without in the acquired p.Thr790Met resistant mutation. |
| Invitae | RCV001861477 | SCV002205924 | uncertain significance | EGFR-related lung cancer | 2024-01-26 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 724 of the EGFR protein (p.Gly724Ser). This variant is present in population databases (no rsID available, gnomAD 0.01%). This missense change has been observed in individual(s) with lung cancer (PMID: 30610926). ClinVar contains an entry for this variant (Variation ID: 376360). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt EGFR protein function with a positive predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Database of Curated Mutations |
RCV000421183 | SCV000505747 | not provided | Neoplasm of the large intestine | 2016-03-10 | no assertion provided | literature only |